Select Publications

Conference Papers

To MD; Merchant R; Atkinson V; Bedard P; Brenner W; Coello M; Antras JF; Galligan C; Lemech C; Lloyd P; Karanam SM; Margolin K; Mathew M; Prawira A; Thomas S; Twardowski P; Yavari A; Merchant F, 2023, '760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, presented at SITC 38th Annual Meeting (SITC 2023) Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0760

Lee DH; Roohullah A; Cho BC; Lemech CR; De Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin Y; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300998&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

To M; Merchant N; Coello M; Galligan C; Mehta K; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Lloyd P; Antras J; Yavari A; Merchant F, 2022, '743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0743

To M; Merchant F; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Antras J; Lloyd P; Yavari A; Coello M; Merchant N, 2022, '744 Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0744

Lemech C; Dredge K; Bampton D; Hammond E; Clouson A; Waterhouse N; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341

Lemech C; Dredge K; Bampton D; Hammond E; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340

Tran B; Horvath L; Dorff T; Rettig M; Lolkema MP; Machiels J-P; Rottey S; Autio K; Greil R; Adra N; Lemech C; Minocha M; Cheng F-C; Kouros-Mehr H; Fizazi K, 2020, 'Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S507 - S507, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.869

Coward J; Lemech CR; Mislang ARA; Parakh S; Underhill C; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2020, 'A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368309070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Unnikrishnan A; Lim XY; Joshi S; Nunez AC; Vaughan L; Pickford R; Hough S; Davidson S; Fong C; Kenealy M; Hiwase DK; Pasalic L; Mohammed S; Lee L; Passam FH; Spring K; Rebeiro P; Ling S; Fuller S; Presgrave P; Roncolato F; Larsen S; Enjeti AK; Stevenson WS; Tiley C; Campbell PJ; Lemech C; Olivier J; Hertzberg M; Polizzotto MN; Pimanda J, 2019, 'In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-123921

Kuo J; Bampton D; Lemech CR; Brown MP; Stanley A; Chojnowski G; Hammond E; Dredge K; Goldstein D, 2018, 'Preliminary results from a Phase Ib study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, Dublin, pp. E18 - E19, presented at 30th EORTC-NCI-AACR Symposium, IRELAND, Dublin, 13 November 2018 - 16 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461258600037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kuo JC; Roncolato FT; Bahari B; Wharton J; Lemech CR, 2018, 'Conducting early-phase oncology clinical trials: Experience of a dedicated clinical trial unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 154 - 155, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200254&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Plesner T; Arkenau H-T; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; Yeh H; Ahmadi T; Lokhorst HM; Richardson PG, 2015, 'Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.507.507

Plesner T; Arkenau HT; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, ITALY, Milan, pp. 104 - 104, presented at 19th Congress of the European-Hematology-Association, ITALY, Milan, 12 June 2014 - 15 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900251&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Arkenau H-T; Saggese M; Hollebecque A; Mathewson A; Lemech CR; Landers D; Frewer P; Kilgour E; Brooks N, 2014, 'A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2620

Arkenau H-T; Mateo J; Lemech CR; Infante JR; Burris HA; Bang Y-J; Eder JP; Herbst RS; Sharma S; Chung HC; Decordova S; Swales KE; Garrett MD; Loftiss JI; Durante M; Russo MW; Suttle BB; Motwani M; Kumar R; De Bono JS, 2014, 'A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2514

Lemech CR; Ensell L; Paterson J; Eminowicz G; Lowe H; Griffin N; Arora R; Arkenau H-T; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley JA; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2014, 'Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5600

Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech CR; Minnema M; Lassen UN; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.8533

Plesner T; Arkenau T; Lokhorst H; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Cakana A; Brun NC; Basse L; Palumbo A; Richardson PG, 2013, 'Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, presented at 55th Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 07 December 2013 - 10 December 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331385004173&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lemech CR; Newmark J; Arkenau H-T, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice: A multi-institutional multinational survey', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419604404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lemech C; Fontela A; Arkenau H; Chin M; Li S; Liauw WS; Thomas D; De Souza P, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at ASCO Annual Meeting, Chicago, USA, 01 June 2012 - 05 June 2012, http://meeting.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2Fe13585&allch=&submit=Go#abstr-1

Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf


Back to profile page